Immunity and cancer : N. Bonnefoy


Over the past decade, the focus of cancer treatment has shifted from the tumor to the host, with the development of various forms of immune-based therapies that mobilize the immune system to promote or restore an effective anti-tumor immune response. A better understanding of the relationships between cancer cells and cells of the immune system is mandatory to further improve patient’s outcome. As illustrated by our recent work on the CD39/CD73/Adenosine pathway (Perrot I et al. 2019), through a deep and comprehensive analysis of tumor immune microenvironment, the Immunity & Cancer team in close collaboration with clinicians and industrial partners, aims at deciphering immunosuppressive molecular and cellular mechanisms that contribute to tumor escape from immune surveillance and at offering proof-of-concept for new targets and new immune based combined therapies to improve response to conventional therapies such as targeted therapies or radio- and chemo-therapies.


Figure : Tumor cell recognized by a cytotoxic lymphocyte


Glasson Y, Chépeaux L-A, Dumé A-S, Jay P, Pirot N, Bonnefoy N, Michaud H-A A 31-plex panel for high-dimensional single-cell analysis of murine preclinical models of solid tumors by imaging mass cytometry. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.1011617

Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer. 2021;9(7):e002242. doi:10.1136/jitc-2020-002242

Chabab G, Boissière-Michot F, Mollevi C, Ramos J, Lopez-Crapez E, Colombo P-E, Jacot W, Bonnefoy N, Lafont V Diversity of Tumor-Infiltrating, ?? T-Cell Abundance in Solid Cancers. Cells. 2020;9(6). doi:10.3390/cells9061537

Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J-F, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27(8):2411-2425.e9. doi:10.1016/j.celrep.2019.04.091

Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer K, Sanders A, Jiang W, Michaud H-A, Colombo P-E, Bensussan A, Alberici G, Bastid J, Eliaou J-F, Bonnefoy N The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway. Oncotarget. 2017;8(69):113360-113372. doi:10.18632/oncotarget.23008


Team Leader  : Nathalie Bonnefoy

Institut de Recherche en
Cancérologie de Montpellier
Campus Val d’Aurelle
34298 Montpellier cedex 5

Tél. : 33 (0)4 67 61 24 40
Fax : 33 (0)4 67 61 37 87

Discover the team



partners / funding


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés